Good to hear RGS is progressing its immuno-oncolcogy area. The phase 1 ACTIVATE trial has been a challenging recruit and it will be interesting to see the reporting this HY. I addition I have read that RGS is doing pre-clinical work with RGSH4K in combination with an ant PD1 immune checkpoint inhibitor (ICI).
This in combination with its stem cells and secretions areas should be a good news flow coming up.
Ann: Japanese Patent Office to grant patent for cancer vaccine, page-4
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
